ClinicalTrials.gg
Not yet recruitingNCT06524323Updated Jul 29, 2024

A Randomized, Double-blinded, Self-controlled Clinical Study of Intralesional Injection of 5-fluorouracil Plus Triamcinolone for the Treatment of Refractory Nodular Prurigo

A Phase 3 interventional study of 5-fluorouracil Injection and Triamcinolone Acetonide in Nodular Prurigo, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-07-29.

Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 3, Interventional, and Treatment

Phase
Phase 3
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Nodular pruritus is a chronic inflammatory skin disease manifested as individual or multiple highly keratotic nodules with severe itching. The goal of this clinical trial is to compare the efficacy and safety of treating refractory nodular pruritus with intralesional injections of 5-fluorouracil alone or 5-fluorouracil plus triamcinolone acetonide.

Read the detailed description

The study is a single-center, randomized, double-blinded, self-controlled clinical trial and is expected to enroll 60 patients. The trial is set up with a self-control design, comparing the two treated sides on the arms or legs with 1:1 interindividual randomization (right side: triamcinolone acetonide-alone; left side: 5-fluorouracil plus triamcinolone acetonide; or the other way round). Patients who meet all the inclusion criteria and do not meet any of the exclusion criteria are randomly enrolled and receive trial medication treatment. All enrolled patients with receive intralesional injections of the trial medication once every 4 weeks for a total of 12 weeks. For the first 4 weeks after the initial dose, follow-up visits are scheduled every 2 weeks; from weeks 5 to 12, follow-up visits are scheduled every 4 weeks.

02

Conditions studied

  • Nodular Prurigo

Browse trials for

Keywords

  • nodular prurigo
  • 5-fluorouracil
03

In context

Prurigo

38 studies on the registry are indexed under Prurigo; 10 are open to participants now.

This study's planned enrollment of 60 is below the median of 135 across 31 interventional studies indexed under Prurigo.

Browse Prurigo studies →

Lead sponsor

Second Affiliated Hospital, School of Medicine, Zhejiang University is the lead sponsor of 1,047 studies on the registry; 502 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Fully understand and voluntarily sign an form for this experiment;
    1. When signing the informed consent form, the age of male or female participants is ≥ 18 years old and ≤ 70 years old;
    1. During the screening of subjects, the onset time of nodular prurigo was at least 6 months, and it met the diagnostic criteria for nodular prurigo;
    1. Within the 12 weeks before screening, no intralesional injection of triamcinolone acetonide or 5-FU combined with triamcinolone acetonide treatment was received;
    1. Within the specified time window before screening, there is a clear medical history showing that patients who have received any of the following treatment regimens can partially alleviate nodular prurigo but have not been completely cleared:

      1. Continuous use of systemic therapies such as antihistamines, antiepileptic drugs (gabapentin, pregabalin, etc.), , or (methotrexate, cyclosporine, thalidomide, etc.) for the first 4 weeks before screening;
      2. Continuous use of small molecule inhibitors (including tofacitinib/tofacitinib, baritinib/baritinib, Upadacitinib/Upatinib, Abrocitinib/Abrocitinib, ruxolitinib/Lucetinib, filgotinib/Figetinib, lestaurtinib/letatinib, pacritinib/parkatinib, Delgocitinib, SHR0302, etc.) for the first 4 weeks before screening;
      3. Continuous use of biologics (including monoclonal antibodies targeting IL-4, IL-13, IL-31, IgE, etc.) for the first 8 weeks before screening;
      4. Continuous use of phototherapy (such as UVB, PUVA, etc.) for the first 4 weeks before screening;
    1. From the start of screening until the end of the visit, the subject can only continue to use moisturizers and the treatment regimens listed in the Inclusion Criteria 5;
    1. Multiple symmetrically distributed nodules (10-12 nodules on one side) were observed in the trunk and limbs during subject screening;
    1. During the subject screening, the Pruritus Numerical Rating Scale (NRS) score was ≥ 4 points;
    1. For women with reproductive ability and all male subjects, abstinence or must be maintained during the trial period and for 6 months after discontinuation of the trial drug:
    1. The subjects can communicate well and agree to comply with the study and follow-up procedures.

Exclusion criteria

Exclusion Criteria:

    1. Have other inflammatory skin diseases (such as psoriasis), as well as any abnormal skin changes that may affect the evaluation of treatment response for nodular prurigo;
    1. Known or suspected allergy to 5-fluorouracil and its analogs;
    1. Have received aspirin drugs within the first week before screening and need to be taken for a long time, and should not be discontinued;
    1. Within the specified time window before the first administration, individuals with the following infection status:

      1. Patients with active tuberculosis (TB), latent untreated TB, or a history of TB or non-tuberculous mycobacterium infection with potential incomplete treatment within 48 weeks before screening, or patients with TB screening indicating latent TB infection;
      2. The following infections that are active and uncontrolled during screening: positive, active syphilis, positive for hepatitis B with HBV-DNA detection values exceeding the lower limit of quantification, positive anti- antibodies or HCV-RNA positive for hepatitis C;
      3. Screening for bacterial, viral, mycoplasma, parasitic, protozoan, or fungal infections with any clinical symptoms within the first two weeks that require systemic anti-infection treatment, or screening for individuals with active lung infections indicated by chest imaging examination;
      4. Screening for individuals with a history of herpes simplex virus or varicella-zoster virus infection within the first 4 weeks, or those with superficial skin infections that require treatment within the first week but have not recovered;
    1. Individuals with the following serious chronic or acute diseases that have not been controlled:

      1. Have a clear history of arterial or venous thromboembolism within the first 12 weeks of randomization, or have a high-risk state that requires long-term use of anticoagulants to prevent thrombosis;
      2. Individuals with severe heart disease within the first 12 weeks of randomization, including myocardial infarction, heart failure (grade III or IV according to the classification), history of unstable angina, or third-degree atrioventricular block and other life-threatening arrhythmias;
      3. Individuals who have experienced severe trauma or major surgery within the first 4 weeks of randomization;
      4. Serious neurological disorders were present during screening, including acute cerebrovascular diseases within the first 6 months of randomization, previous seizures within the first 4 weeks of randomization or the need for continuous anti-epileptic drug treatment, known or suspected demyelinating neurological disorders during screening, peripheral neuropathy with V5.0 ≥ 2, and any significant neurological dysfunction remaining;
      5. During screening, there were severe mental illness patients, including any severe/unstable mental/psychological illness or somatic illness/symptoms, as well as recent or current suicidal thoughts or behaviors, as well as other researchers who believed they would pose an unacceptable risk to participants in the study, except for those with mild emotional disorders caused by nodular prurigo who do not require antipsychotic or sedative maintenance therapy;
      6. When screening, individuals with known or suspected immunodeficiency diseases, first-degree relatives with hereditary immunodeficiency diseases, or those who have received organ transplants that require sustained ;
      7. There is known or suspected leukopenia during screening;
      8. Individuals with a known or suspected history of thrombocytopenia, coagulation disorders, or dysfunction during screening;
      9. Have other serious and uncontrolled diseases, including severe lung, liver, kidney, endocrine and metabolic, lymphatic system, and connective tissue diseases, etc;
    1. Have the following events within the specified time window before the first administration of the drug:

      1. Individuals with a history of drug abuse, alcohol abuse, or addiction, including those who frequently (>3 times per week) use sedatives, sleeping pills, or tranquilizers;
      2. Individuals who have received any clinical trial treatment of drugs or medical devices within the first 4 weeks of randomization;
      3. When screening, there is a clear plan to undergo major surgeries during the study period, or significant changes in work and life status that may affect compliance with the study;
    1. During screening or baseline visits, laboratory tests did not meet the following criteria:

      1. Blood routine: WBC count ≥ lower limit of normal (LLN), ≥ LLN, lymphocyte count ≥ LLN, platelet count ≥ 100 × 109/L, ≥ 100g/L;
      2. Liver function indicators: \<2.0 x , AST\<2.0 x ULN, total \<1.5 x ULN;
      3. Renal function indicators: (eGFR) ≥ 60 ml/min/1.73 m2;
      4. Blood glucose: Fasting blood glucose\<8.9mmol/L (allowed to be controlled by hypoglycemic drugs);
      5. Blood pressure: systolic blood pressure\<160mmHg and/or diastolic blood pressure\<100mmHg (allowed to be controlled by no more than two antihypertensive drugs);
      6. Coagulation function indicators: PT\<1.5 x ULN, \<1.5 x ULN, INR\<1.5;
      7. 12 lead \<480ms, cardiac ultrasound ≥ lower limit of normal value;
    1. The researchers believe that any other subjects who are unsuitable to participate in this trial.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Control side

    Intralesional injection of triamcinolone acetonide alone

    Drug: Triamcinolone Acetonide

  • Experimental
    Experimental side

    Intralesional injection of 5-fluorouracil plus triamcinolone acetonide

    Drug: 5-fluorouracil Injection

Interventions

  • The mixture contains 2mL of triamcinolone acetonide injection and 4mL of 5-fluorouracil injection, which is diluted with saline to 10mL.

  • The mixture contains 2mL of triamcinolone acetonide injection which is diluted with saline to 10mL.

06

What researchers measure

Primary outcomes

  1. Clearance rate

    The proportion of subjects with a clearance rate of ≥ 90%

    Time frame: Week 12 after administration

  2. NRS score

    The proportion of subjects whose NRS score improved by ≥ 4 points from baseline

    Time frame: Week 12 after administration

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06524323
Responsible party
Xiaoyong Man (Director, Second Affiliated Hospital, School of Medicine, Zhejiang University) — Principal investigator
First posted
Jul 29, 2024
Start date
Sep 1, 2024 (estimated)
Primary completion
Aug 31, 2026 (estimated)
Completion
Aug 31, 2026 (estimated)
Last update
Jul 29, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluorouracil

Start the discussion